Authors
Latest:
Tips for Improving the Interpretation and Reporting of PSMA-PET Imaging ResultsTony Abraham, DO, MPA, outlines the limitations of PSMA-PET imaging and discusses the importance of multidisciplinary care in overcoming challenges surrounding the interpretation and reporting of imaging results.
Latest:
Arvin K. George, MD, provides update on the PRESERVE trialThe PRESERVE trial is evaluating the safety and effectiveness of Irreversible electroporation for prostate tissue ablation.
Latest:
PINNACLE trial aims to confirm pilot success with BPH drug-coated balloon catheterThe drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.
Latest:
Sandip Prasad, MD, on UGN-102’s potential as a non-surgical option in NMIBC"The durability response for these patients was impressive given the fact that these patients were those who, by definition and by inclusion criteria, were recurrent within a year at [baseline]," says Sandip M. Prasad, MD.
Latest:
Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression“In the setting of widespread metastatic progression or failure, we typically prefer more systemic therapy with metastasis-directed therapy for symptomatic sites,” says Kate H. Gessner, MD, PhD.
Latest:
Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC"The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
Latest:
Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate CancerExperts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Latest:
A physician’s advice for defusing patient angerRebekah Bernard, MD, provides tips for improving interactions with patients who are angry.
Latest:
Urology Practice advice: prioritize billing and coding oversightWhen a miscoded procedure is the result of substantial negligence or fraud, it can be detrimental to a medical practice or physician.
Latest:
Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.
Latest:
Tim Richardson, MD, on genetic testing in the era of targeted therapies“Before long, what we do, how we do it, and when we do it might solely be based off of those genetic testing results,” says Tim Richardson, MD.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Matthew Cooperberg, MD, on racial disparities in prostate, bladder cancer outcomes“Black patients have over 2-fold excess mortality compared to White men, and that has been fairly consistent; the actual rate ratio has hovered between 2 and 2.5 for many years,” says Matthew R. Cooperberg, MD, MPH.
Latest:
Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC"Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.
Latest:
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasionThe AI tool outperformed MRI in assessing for SVI.
Latest:
Addressing Remaining Unmet Needs in mCRPCPanelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize sequencing decisions and identify which patients will benefit most from specific therapies or combinations, particularly as the treatment landscape becomes increasingly complex.
Latest:
Madison Wahlen on navigating the impact of the BCG shortage“Some of the main implications for urologists is that the risk adapted utilization of BCG, which has been implemented as guidelines, should continue,” says Madison M. Wahlen.
Latest:
Urologic Consultants has joined Solaris HealthLeading West Michigan practice now affiliated with nation’s largest urological healthcare management company
Latest:
Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer"I'm hopeful that the decisions are more informed in terms of actual science," says Daniel Kwon, MD.
Latest:
Future Directions for Imaging and Biopsy in Prostate CancerThe panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.
Latest:
Radical nephrectomy before or after systemic therapy for mRCCRecent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.
Latest:
How text messaging can be a valuable tool for your practiceHere are seven ways texting can improve healthcare revenue and decrease costs.
Latest:
Integrating video visits into urologic training"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Latest:
The evolving role of microRNAs in testicular cancer management"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
Latest:
New Drug Application initiated with FDA for TAR-200 for NMIBCThe NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.
Latest:
Online reviews are crucial to maintaining a thriving health care practiceIndependent health care practices rely on online ratings and reviews to attract new patients and establish themselves as leading, recognizable providers in their community.
Latest:
Managing your online reputation in health careWhile online reviews are critical in any industry, patient expectations are simply different when it comes to health care.
Latest:
Dayna R. Smerina and Amy M. Pearlman, MD, discuss their research in sexual medicineSmerina and Pearlman discuss recent research collaborations in the field of sexual medicine.
Latest:
The importance of PSADT in high-risk, biochemically recurrent prostate cancer"We need to be aware that patients have options for treatment of high-risk biochemical recurrence, and in order to identify that they have high-risk biochemical recurrence...we need to calculate PSA doubling time,” says Alicia Morgans, MD, MPH.
